Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning

Sophia S. Wang, Dominic J. Smiraglia, Yue Zhong Wu, Srimoyee Ghosh, Janet S. Rader, Kathleen R. Cho, Thomas A. Bonfiglio, Ritu Nayar, Christoph Plass, Mark E. Sherman

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Aberrant methylation of CpG islands in gene promoters often represents an early clonal event in carcinogenesis. Accordingly, defining methylation profiles may be useful for developing marker panels for early detection or predicting the risk of cancer precursors. To identify specific genes frequently methylated in cervical cancer, we conducted methylation profiling of 20 primary human cervical cancers using Not I-based restriction landmark genomic scanning (RLGS). Of 2,172 RLGS fragments analyzed (average, 1,753 CpG islands per patient), 186 RLGS fragments were lost in at least one tumor and 40 were lost in three or more. Methylation was identified in 19 (95%) of 20 tumor samples compared with normal DNA. Bisulfite sequencing was conducted to confirm RLGS results. Of the confirmed markers frequently methylated, we developed Methylight assays for two corresponding genes, nucleolar protein 4 (NOL4), and lipoma HMGIC fusion partner-like protein 4 (LHFPL4), which were methylated in 85% and 55% of cancers, respectively. Using these assays, we further confirmed frequent CpG island methylation in the original cancers and in another independent series of 15 cervical cancers. We also showed methylation at a reduced frequency in a set of carefully reviewed cytology specimens demonstrating cells exfoliated from cancer precursor lesions. In summary, we identified, for the first time, NOL4 and LHFPL4 as novel methylation targets specific for cervical cancer. Inclusion of NOL4 and LHFPL4 in evaluating methylation panels for early detection, risk prediction, and etiologic research on cervical cancer is warranted.

Original languageEnglish (US)
Pages (from-to)2489-2497
Number of pages9
JournalCancer Research
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2008

Fingerprint

Uterine Cervical Neoplasms
Methylation
CpG Islands
Lipoma
Nuclear Proteins
Neoplasms
Proteins
Genes
Cell Biology
Carcinogenesis
DNA
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. / Wang, Sophia S.; Smiraglia, Dominic J.; Wu, Yue Zhong; Ghosh, Srimoyee; Rader, Janet S.; Cho, Kathleen R.; Bonfiglio, Thomas A.; Nayar, Ritu; Plass, Christoph; Sherman, Mark E.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2489-2497.

Research output: Contribution to journalArticle

Wang, SS, Smiraglia, DJ, Wu, YZ, Ghosh, S, Rader, JS, Cho, KR, Bonfiglio, TA, Nayar, R, Plass, C & Sherman, ME 2008, 'Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning', Cancer Research, vol. 68, no. 7, pp. 2489-2497. https://doi.org/10.1158/0008-5472.CAN-07-3194
Wang, Sophia S. ; Smiraglia, Dominic J. ; Wu, Yue Zhong ; Ghosh, Srimoyee ; Rader, Janet S. ; Cho, Kathleen R. ; Bonfiglio, Thomas A. ; Nayar, Ritu ; Plass, Christoph ; Sherman, Mark E. / Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2489-2497.
@article{48e8a3e3c508416abde4750940736d19,
title = "Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning",
abstract = "Aberrant methylation of CpG islands in gene promoters often represents an early clonal event in carcinogenesis. Accordingly, defining methylation profiles may be useful for developing marker panels for early detection or predicting the risk of cancer precursors. To identify specific genes frequently methylated in cervical cancer, we conducted methylation profiling of 20 primary human cervical cancers using Not I-based restriction landmark genomic scanning (RLGS). Of 2,172 RLGS fragments analyzed (average, 1,753 CpG islands per patient), 186 RLGS fragments were lost in at least one tumor and 40 were lost in three or more. Methylation was identified in 19 (95{\%}) of 20 tumor samples compared with normal DNA. Bisulfite sequencing was conducted to confirm RLGS results. Of the confirmed markers frequently methylated, we developed Methylight assays for two corresponding genes, nucleolar protein 4 (NOL4), and lipoma HMGIC fusion partner-like protein 4 (LHFPL4), which were methylated in 85{\%} and 55{\%} of cancers, respectively. Using these assays, we further confirmed frequent CpG island methylation in the original cancers and in another independent series of 15 cervical cancers. We also showed methylation at a reduced frequency in a set of carefully reviewed cytology specimens demonstrating cells exfoliated from cancer precursor lesions. In summary, we identified, for the first time, NOL4 and LHFPL4 as novel methylation targets specific for cervical cancer. Inclusion of NOL4 and LHFPL4 in evaluating methylation panels for early detection, risk prediction, and etiologic research on cervical cancer is warranted.",
author = "Wang, {Sophia S.} and Smiraglia, {Dominic J.} and Wu, {Yue Zhong} and Srimoyee Ghosh and Rader, {Janet S.} and Cho, {Kathleen R.} and Bonfiglio, {Thomas A.} and Ritu Nayar and Christoph Plass and Sherman, {Mark E.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-3194",
language = "English (US)",
volume = "68",
pages = "2489--2497",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning

AU - Wang, Sophia S.

AU - Smiraglia, Dominic J.

AU - Wu, Yue Zhong

AU - Ghosh, Srimoyee

AU - Rader, Janet S.

AU - Cho, Kathleen R.

AU - Bonfiglio, Thomas A.

AU - Nayar, Ritu

AU - Plass, Christoph

AU - Sherman, Mark E.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Aberrant methylation of CpG islands in gene promoters often represents an early clonal event in carcinogenesis. Accordingly, defining methylation profiles may be useful for developing marker panels for early detection or predicting the risk of cancer precursors. To identify specific genes frequently methylated in cervical cancer, we conducted methylation profiling of 20 primary human cervical cancers using Not I-based restriction landmark genomic scanning (RLGS). Of 2,172 RLGS fragments analyzed (average, 1,753 CpG islands per patient), 186 RLGS fragments were lost in at least one tumor and 40 were lost in three or more. Methylation was identified in 19 (95%) of 20 tumor samples compared with normal DNA. Bisulfite sequencing was conducted to confirm RLGS results. Of the confirmed markers frequently methylated, we developed Methylight assays for two corresponding genes, nucleolar protein 4 (NOL4), and lipoma HMGIC fusion partner-like protein 4 (LHFPL4), which were methylated in 85% and 55% of cancers, respectively. Using these assays, we further confirmed frequent CpG island methylation in the original cancers and in another independent series of 15 cervical cancers. We also showed methylation at a reduced frequency in a set of carefully reviewed cytology specimens demonstrating cells exfoliated from cancer precursor lesions. In summary, we identified, for the first time, NOL4 and LHFPL4 as novel methylation targets specific for cervical cancer. Inclusion of NOL4 and LHFPL4 in evaluating methylation panels for early detection, risk prediction, and etiologic research on cervical cancer is warranted.

AB - Aberrant methylation of CpG islands in gene promoters often represents an early clonal event in carcinogenesis. Accordingly, defining methylation profiles may be useful for developing marker panels for early detection or predicting the risk of cancer precursors. To identify specific genes frequently methylated in cervical cancer, we conducted methylation profiling of 20 primary human cervical cancers using Not I-based restriction landmark genomic scanning (RLGS). Of 2,172 RLGS fragments analyzed (average, 1,753 CpG islands per patient), 186 RLGS fragments were lost in at least one tumor and 40 were lost in three or more. Methylation was identified in 19 (95%) of 20 tumor samples compared with normal DNA. Bisulfite sequencing was conducted to confirm RLGS results. Of the confirmed markers frequently methylated, we developed Methylight assays for two corresponding genes, nucleolar protein 4 (NOL4), and lipoma HMGIC fusion partner-like protein 4 (LHFPL4), which were methylated in 85% and 55% of cancers, respectively. Using these assays, we further confirmed frequent CpG island methylation in the original cancers and in another independent series of 15 cervical cancers. We also showed methylation at a reduced frequency in a set of carefully reviewed cytology specimens demonstrating cells exfoliated from cancer precursor lesions. In summary, we identified, for the first time, NOL4 and LHFPL4 as novel methylation targets specific for cervical cancer. Inclusion of NOL4 and LHFPL4 in evaluating methylation panels for early detection, risk prediction, and etiologic research on cervical cancer is warranted.

UR - http://www.scopus.com/inward/record.url?scp=42049110756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049110756&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-3194

DO - 10.1158/0008-5472.CAN-07-3194

M3 - Article

C2 - 18381458

AN - SCOPUS:42049110756

VL - 68

SP - 2489

EP - 2497

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -